ArticleNPJ breast cancer2021

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.

Tomás Pascual et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.